A Multicenter, Open-Label, Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 11 Jul 2014
Price : $35 *
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors AbbVie
- 31 Aug 2018 Biomarkers information updated
- 29 May 2014 Status changed from recruiting to withdrawn prior to enrolment; according to ClinicalTrial.gov record.
- 25 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.